TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8495323

Group type: EXPERIMENTAL
Intervention: Acute transverse colostomy, suture and omental covering of a visible perforation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acute resection without primary anastomosis
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exteriorization of both lumens
Number of subjects: 62

Group type: COMPARATOR
Intervention: Colostomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acute resection
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acute colostomy
Number of subjects: 62
Study: 3320880

Group type: EXPERIMENTAL
Intervention: Combination of 10 mg intramuscular morphine and 10 mg oral cocaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cocaine alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of morphine and cocaine
Number of subjects: 36
Study: 29195117

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 448

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 448

Group type: COMPARATOR
Intervention: Unresectable disease
Number of subjects: 448
Study: 27821103

Group type: EXPERIMENTAL
Intervention: 7‐day residential multidisciplinary team intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6‐week physiotherapist‐led outpatient intervention (conventional care)
Number of subjects: 100
Study: 26037084

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 116
Study: 23086987

Group type: EXPERIMENTAL
Intervention: PharmCAT
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Med‐eMonitor (MM)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 142
Study: 20432354

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MRA) using 20 mL of gadobenate dimeglumine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Volume rendering of 3D MRA
Number of subjects: 25
Study: 17257431

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3 times a week for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 17
Study: 15527629

Group type: EXPERIMENTAL
Intervention: Ramped position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sniff position
Number of subjects: 60
Study: 11806480

Group type: EXPERIMENTAL
Intervention: Er‐YAG laser conditioning (2.94 microm wavelength, 250 micros pulse duration, 300 mJ for enamel, 250 mJ for root surface, 2 Hz repetition rate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acid-etching with 35% phosphoric acid gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study: 9486674

Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg/day + topical corticosteroid (diflucortolone valerate) for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo + topical corticosteroid (diflucortolone valerate) for 6 weeks
Number of subjects: 60
Study: 16856320

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (90 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3143511

Group type: EXPERIMENTAL
Intervention: Transdermal patches containing 0.2 mA electrical current (active)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Transdermal patches containing no electrical current (passive)
Number of subjects: 13
Study: 31387381

Group type: EXPERIMENTAL
Intervention: Outpatient treatment (n = 27 feet) with foot-ankle-hip exercise program, myofascial releasing, and joint and soft tissue mobilization techniques, twice a week for 8 weeks.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Home rehabilitation (n = 26 feet) with stretching and strengthening exercises only, completed independently over 8 weeks.
Number of subjects: 47
Study: 29170075

Group type: EXPERIMENTAL
Intervention: Culturally adapted behavioral activation intervention (REJOICE), 8 sessions, faith-based themes, Scripture, bible studies
Number of subjects: 24

Group type: COMPARATOR
Intervention: Training only
Number of subjects: 24

Group type: COMPARATOR
Intervention: Training + coaching calls
Number of subjects: 24
Study: 27195696

Group type: EXPERIMENTAL
Intervention: Medication Review with Follow-up (MRF) service
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Usual care (Control Group - CG)
Number of subjects: 1403
Study: 24554545

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol, ketamine, and dexmedetomidine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Classic group (general anaesthesia with volatile anaesthetics and opioids)
Number of subjects: 119
Study: 22397344

Group type: EXPERIMENTAL
Intervention: Nurse-community health worker (CHW) team
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community care (CC) group
Number of subjects: 0
Study: 20089952

Group type: EXPERIMENTAL
Intervention: Oral fingolimod 0.5 mg daily
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Oral fingolimod 1.25 mg daily
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 17592343

Group type: EXPERIMENTAL
Intervention: 4 mg/d of recombinant human growth hormone (r-hGH) for 12 weeks
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 2 mg of r-hGH on alternate days for maintenance (weeks 12-36)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 325
Study: 17533709

Group type: EXPERIMENTAL
Intervention: School-based oral health education program
Number of subjects: 0
Study: 12579108

Group type: EXPERIMENTAL
Intervention: Cobra aortic catheter
Number of subjects: 20
Study: 10561055

Group type: EXPERIMENTAL
Intervention: MSSW with 0.2 g/L mineral content
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MSSW with 0.45 g/L mineral content
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MSSW with 5 g/L mineral content
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MSSW with 11 g/L mineral content
Number of subjects: 36
Study: 8966165

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 30
Study: 1990160

Group type: EXPERIMENTAL
Intervention: Reversed vein graft
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: In situ vein graft
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: In situ vein graft (for veins <= 3.0 mm diameter)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Reversed vein graft (for veins <= 3.0 mm diameter)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 125
Study: 6350412

Group type: EXPERIMENTAL
Intervention: Polym (pilocarpine polymer)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plc (traditional pilocarpine salt solution)
Number of subjects: 40
Study: 31382136

Group type: COMPARATOR
Intervention: High-dose prednisone monotherapy (60 mg/day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combination of high-dose prednisone and moderate-dose topiramate (5 mg/kg/day)
Number of subjects: 77
Study: 28350241

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glatiramer acetate (GA)
Number of subjects: 0
Study: 25265994

Group type: EXPERIMENTAL
Intervention: C-MAC(®)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: GlideScope(®)
Number of subjects: 56
Study: 23752090

Group type: EXPERIMENTAL
Intervention: Wii stillness test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Wii agility test
Number of subjects: 30
Study: 22990158

Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo/Sham
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study: 19164351

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 957
Study: 17126035

Group type: EXPERIMENTAL
Intervention: Conscious detection of errors while reading Chinese sentences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unconscious detection of errors while reading Chinese sentences
Number of subjects: 0
Study: 16036029

Group type: EXPERIMENTAL
Intervention: Beta-blockers (specific dosage not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suboptimal doses of beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of beta-blockers (target doses from large-scale studies)
Number of subjects: 0
Study: 12585015

Group type: EXPERIMENTAL
Intervention: Early intervention in established psychosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening measures for high-risk indicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal treatment early in psychosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public health impact of screening
Number of subjects: 0
Study: 10467265

Group type: COMPARATOR
Intervention: Approximately 0.34T, 30 stimuli, once a day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Approximately 0.34T, 30 stimuli, twice a day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Approximately 0.57T, 30 stimuli, twice a day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Approximately 0.80T, 30 stimuli, twice a day
Number of subjects: 49
Study: 7589044

Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg o.d. for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo for 8 weeks
Number of subjects: 19
Study: 1701029

Group type: EXPERIMENTAL
Intervention: A‐64077 (800 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6124186

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alfatesine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enflurane with surgery
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alfatesine with surgery
Number of subjects: 38
Study: 31318128

Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 0
Study: 27311618

Group type: EXPERIMENTAL
Intervention: Vigorous intravenous fluid resuscitation (IVFR) with lactated Ringer's solution (initial bolus of 10 mL/kg before the procedure, 3 mL/kg/h during the procedure, for 8 hours after the procedure, and a post‐procedure bolus of 10 mL/kg)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Standard intravenous fluid resuscitation (IVFR) with lactated Ringer's solution at 1.5 mL/kg/h during and for 8 hours after the procedure
Number of subjects: 510
Study: 26169566

Group type: EXPERIMENTAL
Intervention: Competitive Training (CT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 23802031

Group type: EXPERIMENTAL
Intervention: Participation in nursing documentation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 39
Study: 20094804

Group type: EXPERIMENTAL
Intervention: Reduction in UI episodes (>=50%)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Improvement in I-QOL scores (>=10 points)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall change in daily UI episodes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall change in I-QOL scores
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall change in SF-6D scores
Number of subjects: 59
Study: 18984908

Group type: EXPERIMENTAL
Intervention: Educational quality improvement intervention
Number of subjects: 64
Study: 17007699

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment for primary care (PST-PC) combined with elements from motivational interviewing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCS nurses' interventions
Number of subjects: 0
Study: 12729121

Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy within one week (group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed physiotherapy after three weeks of immobilisation (group B)
Number of subjects: 86
Study: 11051189

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (100 mg in 50 cc of saline)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 8816215

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 40
Study: 1487226

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (G)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Bezafibrate (B)
Number of subjects: 178
Study: 2866672

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 72
Study: 31061021

Group type: EXPERIMENTAL
Intervention: Current clinical practice (300 U/mL)
Number of subjects: 88

Group type: COMPARATOR
Intervention: NMJ-targeted injection (100 U/mL)
Number of subjects: 88
Study: 30594222

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 162 mg administered subcutaneously once weekly for 24 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once weekly for 24 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 24
Study: 27391223

Group type: EXPERIMENTAL
Intervention: Amlodipine, Chlorthalidone, or Lisinopril (antihypertensive treatment)
Number of subjects: 31250
Study: 24840230

Group type: EXPERIMENTAL
Intervention: High levels of physical activity before diagnosis
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: High levels of physical activity after diagnosis
Number of subjects: 521

Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 521
Study: 22471345

Group type: EXPERIMENTAL
Intervention: Tacrolimus 1.5-3 ng/ml
Number of subjects: 224

Group type: COMPARATOR
Intervention: Tacrolimus 4-7 ng/ml
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Everolimus plus tacrolimus minimization
Number of subjects: 224
Study: 20438585

Group type: EXPERIMENTAL
Intervention: Combined Mathieu and Snodgrass urethroplasty
Number of subjects: 101

Group type: COMPARATOR
Intervention: Mathieu urethroplasty
Number of subjects: 101

Group type: COMPARATOR
Intervention: Snodgrass urethroplasty
Number of subjects: 101
Study: 18041050

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM) subjects during isometric exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM) subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17425231

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (53 hours)
Number of subjects: 26
Study: 15573919

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (100 ml saline)
Number of subjects: 50
Study: 10886047

Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine 150 mg b.d.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Calcium carbonate antacids
Number of subjects: 155
Study: 9376042

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1 mg/kg/h after a priming dose of 1 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyrate (25 mg/kg/h after a priming dose of 25 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 45
Study: 8322373

Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) within 90 minutes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo within 90 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) from 91 to 180 minutes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo from 91 to 180 minutes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 27
Study: 3539623

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 200 mg once daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 200 mg twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31990061

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31061057

Group type: EXPERIMENTAL
Intervention: Urethral training (personalised pelvic floor muscle training programme)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Conventional training (maximal pelvic floor muscle contraction assessed by digital rectal examination)
Number of subjects: 363

Group type: COMPARATOR
Intervention: No training
Number of subjects: 363
Study: 30086538

Group type: EXPERIMENTAL
Intervention: Yoga therapy (60 min sessions for 8 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 70
Study: 26863442

Group type: EXPERIMENTAL
Intervention: SHAM (0.1 g·kg(‐1) NaCl, 4 mL·kg(‐1) carbonated water, and 1 mL·kg(‐1) squash)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLA (0.1 g·kg(‐1) sodium chloride (NaCl), 4 mL·kg(‐1) tap water, and 1 mL·kg(‐1) squash)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SHAM
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 8
Study: 24736440

Group type: EXPERIMENTAL
Intervention: Zidovudine dosed according to World Health Organization weight bands
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Higher doses of zidovudine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Younger and underweight children
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Zidovudine exposure
Number of subjects: 45
Study: 22648714

Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake of ≥10 mg/d
Number of subjects: 9514
Study: 19333002

Group type: EXPERIMENTAL
Intervention: Shan 5
Number of subjects: 400

Group type: COMPARATOR
Intervention: Easyfive
Number of subjects: 400

Group type: COMPARATOR
Intervention: TritanrixHB + Hiberix
Number of subjects: 400
Study: 17891596

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (10 mg/day on days 1-14)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (days 15-28 of each cycle)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dydrogesterone and Placebo
Number of subjects: 104
Study: 14693594

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine with 10% dextrose
Number of subjects: 8

Group type: COMPARATOR
Intervention: 2-chloroprocaine with saline
Number of subjects: 8
Study: 12411035

Group type: EXPERIMENTAL
Intervention: CSEA group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nitrous oxide group
Number of subjects: 300

Group type: COMPARATOR
Intervention: CSEA group, Nitrous oxide group, Control group
Number of subjects: 300
Study: 9526519

Group type: EXPERIMENTAL
Intervention: Supranormal oxygen delivery and consumption therapy (volume expansion and dobutamine 3 to 15 micrograms/kg/min for 12 hours)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal hemodynamic values therapy (control group)
Number of subjects: 34
Study: 7976820

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 7
Study: 2498513

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GSTM) 50 mg IM weekly + placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 12.5 mg weekly (oral and noncycled) + placebo
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both treatments (GSTM and MTX)
Number of subjects: 35
Study: 31168085

Group type: EXPERIMENTAL
Intervention: Iron supplementation (specific dosage and duration not mentioned)
Number of subjects: 1015
Study: 28608447

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study: 26138912

Group type: EXPERIMENTAL
Intervention: Recursive partitioning analysis (RPA)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS)
Number of subjects: 703
Study: 23962828

Group type: EXPERIMENTAL
Intervention: Neurocognitive Individualized Training (NIT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Social Skills Individualized Training (SSIT)
Number of subjects: 72
Study: 20959555

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 19472437

Group type: EXPERIMENTAL
Intervention: Triple combination containing acetylsalicylic acid, paracetamol, and caffeine (randomized phase)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Single agents acetylsalicylic acid and paracetamol (randomized phase)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Triple combination containing acetylsalicylic acid, paracetamol, and caffeine (open-label phase)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Single agents acetylsalicylic acid, paracetamol, and ibuprofen (open-label phase)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Single agents acetylsalicylic acid and paracetamol (open-label phase)
Number of subjects: 1734
Study: 17301210

Group type: EXPERIMENTAL
Intervention: Durable Display at Discharge (3D)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Medication Discharge Worksheet (MDW)
Number of subjects: 138
Study: 15482446

Group type: EXPERIMENTAL
Intervention: Emotional statements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral statements
Number of subjects: 0
Study: 15281970

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (single drop)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (single drop)
Number of subjects: 23
Study: 11059636

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8 or 16 mg once daily
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 9216967

Group type: EXPERIMENTAL
Intervention: Rebreathing expired air, face covered by bedding material
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Exposure to hypercarbia, face uncovered
Number of subjects: 41
Study: 8444272

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (750 mg daily for 2-3 weeks)
Number of subjects: 7